AMPE - Ampio Pharmaceuticals, Inc.

0.2926
0   0%

Share volume: 9
Last Updated: 03-06-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.17%

PREVIOUS CLOSE
CHG
CHG%
$0.29
0.00
0.00%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
0%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 0%
Performance
5 Days
0   0%
1 Month
2,826.00%
3 Months
5,526.92%
6 Months
10,737.04%
1 Year
10,737.04%
2 Year
10,737.04%
Key data
Stock price
$0.29
P/E Ratio 
N/A
DAY RANGE
$0.01 - $0.29
EPS 
N/A
52 WEEK RANGE
$0.00 - $0.29
52 WEEK CHANGE
$10,737.04
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
0.000
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
N/A
AVERAGE 10 VOLUME 
$354
AVERAGE 30 VOLUME 
$651
Company detail
CEO: Michael A. Martino
Region: US
Website: ampiopharma.com
Employees: 20
IPO year: 2022
Issue type:
Market: OTCM
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Ampio Pharmaceuticals, Inc. focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial. AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation, AP-019, an Inhaled Ampion treatment.

Recent news